{"entity":{"id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","aka":[],"tldr":"A phase 1/2 trial of capecitabine and pembrolizumab in triple-negative breast cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.","summary":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine is a phase 1/2, randomised interventional study registered as NCT06134375 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 204 participants, started 2024-11-26 and due to reach its primary completion in 2031-06-26. Interventions recorded: Tetrathiomolybdate; Capecitabine; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer; Residual Disease. Triple-negative eligibility wording from the registry: \"Patients must have histologically confirmed breast malignancy that is Triple negative tumors as defined as ER and PR \\<1% and HER2 negative as per ASCO/CAP guidelines\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06134375","url":"https://clinicaltrials.gov/study/NCT06134375"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["capecitabine","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06134375","phase":"1/2","setting":"Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients With Breast Cancer at High Risk of Recurrence","sponsor":"Dartmouth-Hitchcock Medical Center","enrolled":204,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06134375/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}